Ruxolitinib is Associated With Improved Renal Function in Patients With Primary Myelofibrosis
A retrospective study sought to determine if treatment of myeloproliferative neoplasms with ruxolitinib may have nephroprotective effects.
Essential Thrombocythemia
Age at Diagnosis of Myeloproliferative Neoplasm Affects Pattern of Thrombotic Events but Not Mortality Risk
A retrospective study compared disease progression and mortality rates in younger patients with MPNs vs historical controls of older patients with MPNs.
Myeloproliferative Neoplasm Symptom Burden High for UK Patients, Physicians
An analysis of responses to the 2017 Landmark Survey revealed that disease-burden symptoms of MPN is challenging for both patients with the disease and their physicians.
No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis
A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia
A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML
A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.
Impact of ET Treatments on Secondary Malignancies Not Statistically Significant
Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.
JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia
Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
Next post in Myeloproliferative Neoplasms
